angina pectoris
Conditions
Interventions
nitroglycerin 25 mg/day is transdermally administered for 7 days
nitroglycerin 25 mg/day and quercetin 1000mg/day are administered for 7 days
Sponsors
SOUSEIKAI Fukuoka Mirai Hospital, Clinical Research Center
Graduate School of Medical Sciences, Kyushu Umiversity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Japanese healthy volunteers who are older than 20 and younger than 45 Volunteers who have ALDH2 *1/*1 or *2/*2
Exclusion criteria
Exclusion criteria: 1.History of cardiovascular disease 2.Severe hepatic or renal dysfunction 3.Volunteers who received other clinical study drug within 30 days 4.Woman who is pregnant or possibly be pregnant 5.History of severe allergy or allergic reaction to the drugs which are used in the present study 6.History of heart disease, glaucoma, peptic ulcer and aspirin-induced asthma 7.volunteers who have smoking habit 3 months before the start of this study 8.On medical treatment (exclude NSAIDs and sleeping pills taken as needed) 9.On medical treatment of phosphodiesterase 5 or agents with guanylate cyclase stimulating effect 10.systolic blood pressure<90 mmHg 11.Body weight <40 kg or >90 kg 12.Not appropriate to this study by other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relation between ALDH2 polymorphisms and the values of flow-mediated dilation, and oxidative stress (malondialdehyde). | — |
Secondary
| Measure | Time frame |
|---|---|
| Relation between ALDH2 polymorphisms and blood pressure, pulse rate. Relation between ALDH2 polymorphisms and the rate of adverse events. | — |
Countries
Japan
Contacts
Public ContactTatsuya Yoshihara
SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center
Outcome results
None listed